Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Revenues Are Not Doing Enough For Some Investors
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Barclays analyst Balaji Prasad maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
Jefferies analyst Glen Santangelo maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success
Teva Pharmaceutical's Movement Disorder Drug Shows Sustained Improvement in Extension Study
Reported Saturday, Teva Unveils Data on UZEDY Injection Switching Strategy for Schizophrenia Treatment at ECNP
Reported Saturday, Teva's New Schizophrenia Treatment TEV-749 Meets Key Endpoints in Phase 3 Study